A New Risk Scheme to Predict Warfarin-Associated Hemorrhage The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.

19:20 EDT 24th May 2015 | BioPortfolio

Summary of "A New Risk Scheme to Predict Warfarin-Associated Hemorrhage The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study."

The purpose of this study was to develop a risk stratification score to predict warfarin-associated hemorrhage.

Affiliation

Department of Medicine, University of California, San Francisco, San Francisco, California.

Journal Details

This article was published in the following journal.

Name: Journal of the American College of Cardiology
ISSN: 1558-3597
Pages: 395-401

Links

PubMed Articles [16312 Associated PubMed Articles listed on BioPortfolio]

Resuming anticoagulation after hemorrhage: A practical approach.

Most patients who suffer a hemorrhage while on long-term anticoagulant therapy continue to be at risk of thrombosis. Physicians often need to reconsider the need for anticoagulation in view of the ris...

Factors Driving Anticoagulant Selection in Patients With Atrial Fibrillation in the United States.

With the introduction of novel oral anticoagulants (NOACs), the factors driving anticoagulant selection in atrial fibrillation (AF) in real-world practice are unclear. The goal was to examine whether ...

Anticoagulation clinic versus a traditional warfarin management model.

Warfarin is the most commonly prescribed oral anticoagulant. The management of warfarin is challenging, and current guidelines fail to include a model to assist practitioners in optimizing therapeutic...

Anticoagulation: Monitoring of Patients Receiving Anticoagulation.

For patients with acute venous thromboembolism treated with warfarin, parenteral anticoagulation should be continued for a minimum of 5 days and until the international normalized ratio (INR) is 2 or ...

Anticoagulation: Choosing the Optimal Anticoagulant.

The risks of bleeding and thrombosis should be considered in decisions on whether to initiate anticoagulation therapy. Oral anticoagulation is indicated for patients with nonvalvular atrial fibrillati...

Clinical Trials [2966 Associated Clinical Trials listed on BioPortfolio]

Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy

The main objective of this study is to assess the effectiveness of low dose Vitamin K1 (200 micrograms per day) at improving anticoagulation control in unstable patients on warfarin. This ...

Clarification of Optimal Anticoagulation Through Genetics

Individuals taking warfarin often need frequent dose changes as the international normalized ratio (INR) gets too high or too low which could result in a higher risk of thromboembolism, bl...

The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

The purpose of this study is to determine if osteoporosis is an unrecognized complication of chronic anticoagulation with warfarin.

Testing Strategies to Improving Warfarin Adherence

We are performing a research study to learn more about the control of an individual's blood thinning (anticoagulation) on warfarin. Individuals from an anticoagulation clinic are being as...

Patient Self Testing of Warfarin Therapy

To test the hypothesis that home international normalised ratio (INR) monitoring with supervised patient self-testing (PST)can provide comparable or superior time in therapeutic range (TTR...

Medical and Biotech [MESH] Definitions

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

The application of molecular biology to the answering of epidemiological questions. The examination of patterns of changes in DNA to implicate particular carcinogens and the use of molecular markers to predict which individuals are at highest risk for a disease are common examples.

A scheme which provides reimbursement for the health services rendered, generally by an institution, and which provides added financial rewards if certain conditions are met. Such a scheme is intended to promote and reward increased efficiency and cost containment, with better care, or at least without adverse effect on the quality of the care rendered.

Reduction of high-risk choices and adoption of low-risk quantity and frequency alternatives.

Hemorrhage within the orbital cavity, posterior to the eyeball.

Search BioPortfolio:
Loading
Advertisement
Advertisement

Searches Linking to this Article